European Deep Brain Stimulation (DBS) Depression Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder (TR-MDD), single or recurrent episode on mood as measured by the MADRS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Brain Stimulation for Treatment-Refractory Major Depression

NCT00122031

Depression

COMPLETED PHASE1

A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression

NCT01801319

Treatment Resistant Depression Depressive Disorder

UNKNOWN NA

Deep Brain Stimulation in Treatment Resistant Depression

NCT01435148

Treatment Resistant Depression

UNKNOWN NA

DBS for Treatment Resistant Depression

NCT01983904

Depressive Disorder, Treatment-Resistant

COMPLETED NA

Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder

NCT01569711

Major Depressive Disorder, Recurrent, Unspecified

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The European Study was a prospective, multicenter, double-blind, randomized study comparing high frequency stimulation (130 Hz) to low frequency stimulation (20 Hz). Subjects underwent 2 baseline evaluations by 2 separate psychiatrists and were implanted with the Libra DBS system. Subjects were randomized to receive either high or low frequency stimulation. The primary endpoint was evaluated after 6 months of stimulation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group B

Low Programming

Group Type ACTIVE_COMPARATOR

Deep Brain Stimulation

Intervention Type DEVICE

Low Programming

Group A

Normal Programming

Group Type EXPERIMENTAL

Deep Brain Stimulation

Intervention Type DEVICE

Normal DBS Programming

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep Brain Stimulation

Normal DBS Programming

Intervention Type DEVICE

Deep Brain Stimulation

Low Programming

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women (non-pregnant) age is 21-70 years;
* Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition, Text Revision, 2000 (DSM-IV-TR) criteria derived from the Mini International Neuropsychiatric Interview (MINI);
* First episode onset before age 45;
* Current episode \> 12 month duration;
* In the current episode: Documented resistance to a minimum of 4 adequate depression treatments from at least 3 different categories;
* In adult lifetime (\>21 year of age) have experience a period of wellness as defined by DSM IV criteria;
* MADRS score ≥22 at 2 separate baseline visits, rated by 2 separate psychiatrists;
* Global Assessment of Functioning (GAF) score \<50;
* Mini-mental state examination (MMSE) score \>24;
* No change in current antidepressant medication regimen or medication free for at least 4 weeks prior to study entry;
* Able to give informed consent in accordance with institutional policies;

Exclusion Criteria

* A diagnosis of bipolar I or bipolar II disorder by DSM-IV-TR criteria, derived from the MINI;
* Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality Disorders Sections 301.7 - 301.83, preferably screened via Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II) at Baseline visit (optional);
* In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;

Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No